TITLE

A decade of experience with an inpatient pneumococcal vaccination program

AUTHOR(S)
ROBKE, JILL TRUE; WOODS, MARK
PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/15/2010, Vol. 67 Issue 2, p148
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. A hospital's experience with an inpatient pneumococcal vaccination program is described. Summary. Saint Luke's Hospital (SLH) is a 625-bed, tertiary care, referral hospital in Kansas City, Missouri. In a retrospective analysis conducted in 1995 of pneumococcal vaccination rates in patients with community-acquired pneumonia (CAP) at the hospital, only 1 of 84 patients had documented pneumococcal vaccination. These results led to efforts to improve assessment of vaccination status, documentation of vaccination, and pneumococcal vaccination rates. In 1998, the pharmacy department at SLH conducted a study to examine the impact of pharmacists on pneumococcal vaccination rates through incorporation of vaccination assessment into selected critical pathways. Pharmacists were assigned to screen and educate patients on chosen pathways. When eligible patients were identified in the intervention group, the pharmacist would then contact their physician for authorization to vaccinate. The success of the study led to several notable changes to the pneumococcal vaccination program in 2001. First, the vaccination assessment was moved from selected critical pathways to the admission database of all patients. Second, a collaborative practice agreement was developed to authorize pharmacists to write pneumococcal and influenza vaccine orders for eligible patients per the program's protocol. These two changes led to a dramatic improvement in overall screening and documentation rates of pneumococcal vaccination for patients with CAP and for other at-risk patients. Conclusion. A pneumococcal vaccination program helped a hospital meet regulatory expectations for vaccination of patients with CAP and vaccinated many other at-risk patients.
ACCESSION #
47921877

 

Related Articles

  • Pharmacists able to raise vax rate in high-risk patients.  // PharmacoEconomics & Outcomes News;10/1/2011, Issue 638, p4 

    The article discusses a research study which revealed the success of U.S. pharmacists in identifying at-risk patients and offering additional immunization services, like the pneumococcal vaccine, published in the August 19, 2011 issue of the journal "Vaccine."

  • Curbing a bacterial menace. Foster, Stephan L. // Pharmacy Today;Aug2010 Supplement, p5 

    In this article, the author offers his views on the role played by pharmacists in addressing the pneumococcal immunization gap and reducing the impact of this virulent bacterial threat in the U.S. He believes that pharmacists are in the best position to help increase pneumococcal vaccine uptake...

  • Vaccination delivery by chain pharmacies in California: Results of a 2007 survey. Pilisuk, Tammy; Goad, Jeffery; Backer, Howard // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2010, Vol. 50 Issue 2, p134 

    Objective: To better understand the practice standards and scope of pharmacist-administered vaccination services at chain pharmacies in California. Design: Cross sectional. Setting: California in 2006-2007. Participants: Eight state-level immunization coordinator corporate liaisons to chain...

  • Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for? Heininger, Ulrich // European Journal of Pediatrics. Supplement;2002, Vol. 161, pS125 

    Focuses on the introduction of pneumococcal vaccine to standard immunization programs in Europe. Efficacy, efficiency and safety of pneumococcal conjugate vaccine.

  • Similar antibody levels found among four PCV13 immunization schedules.  // Infectious Disease News;Oct2013, Vol. 26 Issue 10, p48 

    The article discusses a study published in a 2013 issue of "JAMA: The Journal of the American Medical Association" that found similar antibody levels among 13-valent pneumococcal conjugate vaccine (PCV7) immunization schedules for infants.

  • Vaccine Policy Decisions: Tension Between Science, Cost-Effectiveness and Consensus? Zimmerman, Richard Kent // American Family Physician;5/15/2001, Vol. 63 Issue 10, p1919 

    Editorial. Comments on the process used by the working group of the Advisory Committee on Immunization Practices to make policy recommendations for the use of pneumococcal conjugate vaccine. Focus of the working group and the data they have developed; Differences in the position of health...

  • Vaccines.  // Reactions Weekly;5/5/2012, Issue 1400, p38 

    The article describes the case of a 5-month-old boy with diffuse cutaneous mastocytosis who developed systemic, life-threatening generalised bullous eruption after he underwent routine immunisation with Haemophilus influenzae type B, conjugated pneumococcal vaccine, inactivated poliovirus...

  • Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPspA) Elicits Antibodies That Passively Protect Mice from Fatal Infection with Streptococcus pneumoniae Bearing Heterologous PspA. Briles, David E.; Hollingshead, Susan K.; King, Janice; Swift, Amy; Braun, Patricia A.; Park, Moon K.; Ferguson, Laura M.; Nahm, Moon H.; Nabors, Gary S. // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6 

    Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumo-cocci, is known to elicit an antibody in animals that can passively protect mice from infection with Streptococcus pneumoniae. A phase I trial with recombinant PspA showed the protein to be immunogenic in...

  • Method for Ascertaining Denominators for Evaluation of Population Coverage with Pneumococcal Vaccine. Schopflocher, Donald P.; Russell, Margaret L. // Canadian Journal of Public Health;Sep/Oct2003, Vol. 94 Issue 5, p377 

    Background: Immunization programs may collect numerator data for the estimation of pneumococcal vaccine coverage, but program evaluators do not have appropriate denominator data for estimation of pneumococcal vaccine coverage, particularly among those eligible for vaccine on the grounds of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics